New breakthrough in developing more personalized treatments for lung cancer

Article excerpt

Researchers at the University of Barcelona have identified why adenocarcinoma and squamous cell carcinoma, the two main lung cancer types, respond differently to anti-angiogenic drugs that starve tumors of blood vessels. The key lies in the tumor's surrounding environment, specifically in fibroblasts, abundant benign cells that appear to influence how well these therapies work. The findings, published in Cell Death & Disease, could help doctors tailor treatments to individual patients based on their tumor's cellular makeup, potentially improving outcomes for lung cancer patients who currently face limited personalized treatment options.